INOVIQ Ltd (ASX:IIQ)
Australia · Delayed Price · Currency is AUD 0.1750
+0.0100 (6.06%)
Aug 27, 2026, 3:59 PM AEST
INOVIQ Revenue
In the fiscal year ending June 30, 2026, INOVIQ had annual revenue of 2.61M AUD with 44.01% growth. INOVIQ had revenue of 1.12M in the half year ending December 31, 2025, with 59.11% growth.
Revenue
2.61M
Revenue Growth
+17.38%
P/S Ratio
9.42
Revenue / Employee
174.28K
Employees
15
Market Cap
24.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 2.61M | 798.84K | 44.01% |
| Jun 30, 2025 | 1.82M | 253.75K | 16.25% |
| Jun 30, 2024 | 1.56M | 10.36K | 0.67% |
| Jun 30, 2023 | 1.55M | -446.01K | -22.33% |
| Jun 30, 2022 | 2.00M | 726.44K | 57.16% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Healius | 1.37B |
| Australian Clinical Labs | 736.15M |
| Monash IVF Group | 269.39M |
| ImExHS | 28.97M |
| Genetic Signatures | 20.32M |
| Cryosite | 16.70M |
| Microba Life Sciences | 14.90M |
| Genetic Technologies | 9.17M |